Should You Buy Eli Lilly Stock? Here's My Honest Take.

Eli Lilly reported Q1 2026 revenue of $19.8B (+56% YoY) and adjusted EPS up 156%, driven by GLP-1 strength (Mounjaro +125% to $8.7B; Zepbound +80% to nearly $4.2B). Despite the strong growth, the stock screens expensive at 33.4x forward earnings (PEG 1.57) and faces intensifying GLP-1 competition and China price cuts, with added regulatory scrutiny from a U.S. House committee over trial activity in China. Overall, the article frames LLY as a strong long-term compounder but suggests a pullback is possible, recommending a gradual “partial position” approach ahead of the next earnings report (July 30, 2026).

Analysis

LLY remains a quality compounder, but the market is now paying for near-flawless execution in a category that is moving from scarcity pricing to scale competition. The key second-order issue is that GLP-1 leadership is no longer just about demand creation; it is about defending share while managing payer rebates, formulation mix, and manufacturing capacity. That tends to compress margins later than the headline growth phase, so the next leg of upside likely depends on incremental evidence that oral convenience expands total adherence faster than competitors can undercut price.

The relative winners over the next 6-18 months are the companies with either better balance-sheet flexibility or a clearer non-GLP-1 offset. NVO is the most obvious near-term rival to watch, but AMGN and VKTX matter because a credible alternative mechanism or delivery format can cap the category multiple even if their absolute sales are smaller. For incumbents like JNJ and PFE, the read-through is less about direct share loss and more about capital allocation pressure: if GLP-1s continue to re-rate the therapy area, slower-growth pharma names may struggle to justify their own multiple without M&A or buybacks.

The bear case is not that Lilly’s franchise breaks; it is that expectations outrun the pace of monetization. Over the next 1-3 months, China pricing and any sign of slowing U.S. net pricing will matter more than unit growth. Over 6-18 months, the falsifier for the bullish thesis is a guide-down on gross margin or evidence that oral adoption simply substitutes for injectable demand rather than enlarging the addressable market.

Key Decisions for Investors

• Gradually build LLY on 5-8% pullbacks over the next 4-8 weeks; treat it as a quality compounder, not a momentum chase. Risk/reward is favorable only if you avoid paying peak enthusiasm multiples.
• Pair trade: long LLY / short NVO into the next 1-2 quarters if you expect Lilly’s execution and pipeline breadth to outweigh Novo’s competitive pressure. Cover if NVO oral uptake or CagriSema data materially outperforms.
• If already long LLY, hedge valuation risk with a 3-6 month call spread sale against the position rather than outright trimming. The thesis breaks if the stock re-rates down on margin compression, not just on slower top-line growth.
• Watch AMGN and VKTX as event-driven hedges against category complacency; a positive efficacy/safety surprise there would likely compress the whole GLP-1 basket multiple.